Posters

      Comparative Toxicity Assessment of the Harm Reduction Potential of Tobacco-Free Oral Nicotine Products

      Oh, S.; Moses, S.; Aleksa, K.; Mehta, C.; Ma, D.; Coffa, B.

      Conference date
      Mar 11, 2024
      Conference name
      Society of Toxicology (SOT) Annual Meeting and ToxExpo 2024
      Topic
      Summary

      Background and Purpose: The growing use of flavored oral nicotine pouches (NPs) has prompted investigation into their potential health impact. Placed between the lip and gum, these products contain nicotine, flavorings, sweeteners, and plant-based fibers; they are considered harm reduction alternatives due to their low levels of toxicants compared to cigarette smoke. The present work assessed the ability of the ToxTracker® reporter assay to characterize the toxicological profiles of five NPs (ZYN®) and four Swedish snus (General®) products on the U.S. market and compare them to those of two reference tobacco products.

      Methods: ToxTracker was used to profile NP products and snus products with different flavors and determine if they could be toxicologically differentiated from a reference American-style loose moist snuff product (CRP 2.1) and combustible reference cigarettes (1R6F). ToxTracker combines six fluorescent reporter cell lines that are specifically activated by different cellular responses associated with DNA damage, p53 activation, oxidative stress, or protein damage. Reporter gene activation is measured by flow cytometry, and cytotoxicity of the tested compounds is simultaneously determined by relative cell count. NPs and snus were extracted in dimethyl sulfoxide (DMSO) or complete artificial saliva (CAS), and CRP2.1 and total particular matter (TPM) from cigarette smoke were extracted in DMSO.

      Results: Cigarette smoke TPM extract induced cytotoxicity and GFP induction of reporter genes for Srxn1 (oxidative stress), Ddit3 (protein damage), and Btg2 (p53 activation) in both the presence and absence of metabolic activation. CRP2.1 extract did not induce cytotoxicity but increased GFP-Ddit3 expression. The snus extracts in DMSO had similar profiles to the CRP2.1 extract, but GFP-Ddit3 expression was lower and below the positive threshold for three of the four products tested. However, there was no clear induction of GFP-Ddit3 expression when CAS was used for snus extraction. None of the five NPs extracted in DMSO or CAS induced cytotoxicity or GFP expression, suggesting that NP were the least toxic of the tested products.

      Conclusions: This study provides valuable insights into the toxicological profiles of various oral nicotine products compared to cigarettes, highlighting the harm reduction potential of NPs. These findings contribute to the ongoing research on harm reduction strategies in nicotine consumption, emphasizing the importance of considering specific product types and their safety profiles. Further research is needed to understand the long-term effects and broader health implications of these emerging NP products.

      Related Publications

      A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

      Pre-clinical Toxicology

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.